Objective: Betahistine is a histamine-like drug that is considered beneficial in Ménière's disease by increasing cochlear blood flow. Acting as an agonist at the histamine H1-receptor and as an inverse agonist at the H3-receptor, these receptors as well as the adrenergic α2-receptor were investigated for betahistine effects on cochlear blood flow. Materials and Methods: A total of 54 Dunkin-Hartley guinea pigs were randomly assigned to one of nine groups treated with a selection of H1-, H3- or α2-selective agonists and antagonists together with betahistine. Cochlear blood flow and mean arterial pressure were recorded for 3 min before and 15 min after infusion. Results: Blockage of the H3- or α2-receptors caused a suppression of betahistine-mediated typical changes in cochlear blood flow or blood pressure. Activation of H3-receptors caused a drop in cochlear blood flow and blood pressure. H1-receptors showed no involvement in betahistine-mediated changes of cochlear blood flow. Conclusion: Betahistine most likely affects cochlear blood flow through histaminergic H3-heteroreceptors.

Keywords:
Betahistine, H3-receptors, H1-receptors, α2-receptors, Méni&#00E8;reߣs disease, Cochlea, Microcirculation, Fluorescence microscopy
1.
Arai M, Chiba S: Endothelium-dependent vasodilatation mechanisms by histamine in simian but not in canine femoral arterial branches. J Auton Pharmacol 1999;19:267-273.
2.
Baker M, Wayland H: On-line volume flow rate and velocity profile measurement for blood in microvessels. Microvasc Res 1974;7:131-143.
3.
Baldwin DL, Ohlsen KA, Miller JM, Nuttall AL: Cochlear blood flow and microvascular resistance changes in response to hypertonic glycerol, urea, and mannitol infusions. Ann Otol Rhinol Laryngol 1992;101:168-175.
4.
Berlin M, Boyce CW, Ruiz Mde L: Histamine H3 receptor as a drug discovery target. J Med Chem 2011;54:26-53.
5.
Bertlich M, Ihler F, Sharaf K, Weiss BG, Strupp M, Canis M: Betahistine metabolites, aminoethylpyridine, and hydroxyethylpyridine increase cochlear blood flow in guinea pigs in vivo. Int J Audiol 2014:53:753-759.
6.
Brown JN, Nuttall AL: Autoregulation of cochlear blood flow in guinea pigs. Am J Physiol 1994;266:H458-H467.
7.
Canis M, Arpornchayanon W, Messmer C, Suckfuell M, Olzowy B, Strieth S: An animal model for the analysis of cochlear blood flow disturbance and hearing threshold in vivo. Eur Arch Otorhinolaryngol 2010;267:197-203.
8.
Claes J, Van de Heyning PH: Medical treatment of Ménière's disease: a review of literature. Acta Otolaryngol Suppl 1997;526:37-42.
9.
Claes J, Van de Heyning PH: A review of medical treatment for Ménière's disease. Acta Otolaryngol Suppl 2000;544:34-39.
10.
Curwain BP, Holton P, Spencer J: The effect of betahistine on gastric acid secretion and mucosal blood flow in conscious dogs. Br J Pharmacol 1972;46:351-354.
11.
Dziadziola JK, Laurikainen EL, Rachel JD, Quirk WS: Betahistine increases vestibular blood flow. Otolaryngol Head Neck Surg 1999;120:400-405.
12.
Fossati A, Barone D, Benvenuti C: Binding affinity profile of betahistine and its metabolites for central histamine receptors of rodents. Pharmacol Res 2001;43:389-392.
13.
Gbahou F, Davenas E, Morisset S, Arrang JM: Effects of betahistine at histamine H3 receptors: mixed inverse agonism/agonism in vitro and partial inverse agonism in vivo. J Pharmacol Exp Ther 2010;334:945-954.
14.
Gurkov R, Flatz W, Keeser D, Strupp M, Ertl-Wagner B, Krause E: Effect of standard-dose betahistine on endolymphatic hydrops: an MRI pilot study. Eur Arch Otorhinolaryngol 2013;270:1231-1235.
15.
Hunt WH, Fosbinder RJ: A study of some β-2, and 4, pyridylalkylamines. J Pharmacol Exp Ther 1942;75:299-307.
16.
Ihler F, Bertlich M, Sharaf K, Strieth S, Strupp M, Canis M: Betahistine exerts a dose-dependent effect on cochlear stria vascularis blood flow in guinea pigs in vivo. PLoS One 2012a;7:e39086.
17.
Ihler F, Strieth S, Pieri N, Gohring P, Canis M: Acute hyperfibrinogenemia impairs cochlear blood flow and hearing function in guinea pigs in vivo. Int J Audiol 2012b;51:210-215.
18.
Ishikawa S, Sperelakis N: A novel class (H3) of histamine receptors on perivascular nerve terminals. Nature 1987;327:158-160.
19.
James A, Burton MJ: Betahistine for Ménière's disease or syndrome. Cochrane Database Syst Rev 2001;1:CD001873.
20.
James A, Thorp M: Ménière's disease. Clin Evid 2005;14:659-665.
21.
Jeck-Thole S, Wagner W: Betahistine: A retrospective synopsis of safety data. Drug Saf 2006;29:1049-1059.
22.
Kenakin T, Williams M: Defining and characterizing drug/compound function. Biochem Pharmacol 2014;87:40-63.
23.
Klyscz T, Junger M, Jung F, Zeintl H: Cap image - a new kind of computer-assisted video image analysis system for dynamic capillary microscopy (in German). Biomed Tech (Berl) 1997;42:168-175.
24.
Laurikainen E, Miller JM, Nuttall AL, Quirk WS: The vascular mechanism of action of betahistine in the inner ear of the guinea pig. Eur Arch Otorhinolaryngol 1998;255:119-123.
25.
Laurikainen E, Miller JF, Pyykko I: Betahistine effects on cochlear blood flow: from the laboratory to the clinic. Acta Otolaryngol Suppl 2000;544:5-7.
26.
Laurikainen E, Miller JM, Quirk WS, Kallinen J, Ren T, Nuttall AL, Grenman R, Virolainen E: Betahistine-induced vascular effects in the rat cochlea. Am J Otol 1993;14:24-30.
27.
Malinowska B, Godlewski G, Schlicker E: Histamine H3 receptors - general characterization and their function in the cardiovascular system. J Physiol Pharmacol 1998;49:191-211.
28.
Mazenot C, Ribuot C, Durand A, Joulin Y, Demenge P, Godin-Ribuot D: In vivo demonstration of H3-histaminergic inhibition of cardiac sympathetic stimulation by r-α-methyl-histamine and its prodrug BP 2.94 in the dog. Br J Pharmacol 1999;126:264-268.
29.
Ménière P: Congestions cerebrales apoplectiformes. Gaz Med Paris 1861a;16:55.
30.
Ménière P: Pathologie auriculaire: mémoire sur des lésions de l'oreille interne donnant lieu à des symptômes de congestion cérébrale apoplectiforme. Gaz Med Paris 1861b;16:597-601.
31.
Motawaj M, Arrang JM: Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, modulates methamphetamine-induced sensitization in mice. Eur J Neurosci 2011;33:1197-1204.
32.
Nuttall AL: Velocity of red blood cell flow in capillaries of the guinea pig cochlea. Hear Res 1987;27:121-128.
33.
Ohlsen KA, Didier A, Baldwin D, Miller JM, Nuttall AL, Hultcrantz E: Cochlear blood flow in response to dilating agents. Hear Res 1992;58:19-25.
34.
Parsons ME: Histamine receptors: an overview. Scand J Gastroenterol Suppl 1991;180:46-52.
35.
Redon C, Lopez C, Bernard-Demanze L, Dumitrescu M, Magnan J, Lacour M, Borel L: Betahistine treatment improves the recovery of static symptoms in patients with unilateral vestibular loss. J Clin Pharmacol 2011;51:538-548.
36.
Santos-Silva AJ, Cairrao E, Marques B, Verde I: Regulation of human umbilical artery contractility by different serotonin and histamine receptors. Reprod Sci 2009;16:1175-1185.
37.
Strupp M, Thurtell MJ, Shaikh AG, Brandt T, Zee DS, Leigh RJ: Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus. J Neurol 2011;258:1207-1222.
38.
Thorp MA, James AL: Prosper Ménière. Lancet 2005;366:2137-2139.
39.
Tobia AJ, Sternson LA, Walsh GM, LaRocca JP: The role of demethylbetahistine in the depressor response to betahistine in the rat. Proc Soc Exp Biol Med 1974;145:778-781.
40.
Vass Z, Bari F, Barzo P, Czigner J, Bodosi M: Lack of short-term autoregulation in the cochlear microcirculation in guinea pigs. Eur Arch Otorhinolaryngol 1993;250:101-104.
41.
Woldbaek PR, Stromme TA, Sande JB, Christensen G, Tonnessen T, Ilebekk A: Evaluation of a new fiber-optic pressure recording system for cardiovascular measurements in mice. Am J Physiol Heart Circ Physiol 2003;285:H2233-H2239.
42.
Zeintl H, Sack FU, Intaglietta M, Messmer K: Computer-assisted leukocyte adhesion measurement in intravital microscopy. Int J Microcirc Clin Exp 1989;8:293-302.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.